15家公司净利润翻倍

Core Insights - In 2024, 178 listed companies in Sichuan reported a total operating revenue of 1,107.3 billion yuan and a net profit attributable to shareholders of 95.9 billion yuan, with 74% of companies profitable and 42% showing year-on-year profit growth [1] Group 1: Revenue and Profit Performance - Three companies, Sichuan Road and Bridge, Sichuan Changhong, and New Hope, entered the "billion club" with revenues of 107.24 billion yuan, 103.69 billion yuan, and 103.06 billion yuan respectively [2] - Wuliangye led the net profit rankings with 31.85 billion yuan, followed by Luzhou Laojiao with 13.47 billion yuan and Chengdu Bank with 12.86 billion yuan [2] - 15 companies doubled their net profits, while 11 companies turned losses into profits [1] Group 2: Industry Dynamics - The pharmaceutical and biological, food and beverage, and banking sectors emerged as key profit drivers, with 19 pharmaceutical companies forming a comprehensive "R&D + authorization + manufacturing" ecosystem [3] - Baili Tianheng's revenue surged by 936.31% due to an international authorization fee of 800 million USD for its dual-antibody ADC drug, leading to a significant turnaround in profitability [3] - Chengdu Bank achieved a weighted return on equity of 17.81%, ranking high among listed banks [3] Group 3: R&D Investment - Sichuan companies invested a total of 24 billion yuan in R&D in 2024, with 147 companies contributing to this figure [4] - Kelun Pharmaceutical led in R&D investment with 12.3 billion yuan, while New Hope's R&D investment was 4.03 billion yuan, representing 4.66% of its revenue [4] - Tongwei has invested over 11 billion yuan in R&D over the past three years, focusing on cutting-edge photovoltaic technologies [4][5]